Pacira BioSciences Q4 Earnings Call Highlights

Core Insights - Pacira BioSciences reported a transformative year in 2025, achieving significant revenue growth and expanding reimbursement coverage for its flagship product, EXPAREL [4][6]. Group 1: Financial Performance - The company finished 2025 with $726 million in revenue, marking the highest gross margins in its history, while treating over 2.5 million patients [3][6]. - Fourth-quarter EXPAREL sales reached $155.8 million, reflecting approximately 7% volume growth compared to the previous year [9][12]. - For 2026, the company guided total revenue between $745 million and $770 million, with EXPAREL sales projected at $600 million to $620 million [22][24]. Group 2: Market Access and Reimbursement - Pacira exceeded its internal goal by ending 2025 with 102 million covered lives under CMS or commercial coverage outside the surgical bundle, which increased to about 110 million in early 2026 [1][6]. - The NOPAIN Act has been credited as a catalyst for reducing financial barriers to non-opioid postsurgical pain management, with 82% of surveyed physicians viewing it as important for non-opioid stewardship [2][6]. Group 3: Product Development and Pipeline - The company is entering a "data-rich" period with its pipeline, including upcoming clinical milestones for ZILRETTA, iovera°, and PCRX-201 [4][18]. - Pacira plans to initiate a Phase 2 study of PCRX-2002 in bunionectomy patients later this year, which is expected to complement EXPAREL [21]. Group 4: Intellectual Property and Partnerships - The company expanded its intellectual property estate to 21 patents and secured a volume-limited settlement with Fresenius, providing visibility through 2039 [5][16]. - A new partnership with LG Chem aims to commercialize EXPAREL in select Asia-Pacific countries, with revenue contributions expected to begin in 2027 [17]. Group 5: Operational Efficiency and Cost Management - Non-GAAP gross margin improved to 80% in the fourth quarter, attributed to better yields from enhanced production facilities [12][13]. - R&D expenses increased to $34.4 million in the fourth quarter, driven by ongoing development costs for various products [14].